Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
$3.3M
Filings
319
Unique Clients
9
Active Period
1999–2024
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WOMEN'S INTERNATIONAL PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WOMEN'S INTERNATIONAL PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WOMEN'S INTERNATIONAL PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WEDGEWOOD VILLAGE PHARMACY, INC.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Client expense: — · Firm income: $22,500
Matched citations: H.R. 1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WEDGEWOOD VILLAGE PHARMACY, INC.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Client expense: — · Firm income: $22,500
Matched citations: H.R. 1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: VETERINARY PHARMACIES OF AMERICA, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: VETERINARY PHARMACIES OF AMERICA, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: VETERINARY PHARMACIES OF AMERICA, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: BRAIDWOOD MANAGEMENT, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: BRAIDWOOD MANAGEMENT, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: BRAIDWOOD MANAGEMENT, INC.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: PRECISION PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WELLNESS PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WOMEN'S INTERNATIONAL PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Preserving Patient Access to Compounded Medications Act of 2019
2020 · fourth_quarter · Client: WOMEN'S INTERNATIONAL PHARMACY
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Client expense: — · Firm income: $11,250
Matched citations: H.R.1959
Source: Senate LDA